Study of (rATG) in patients preparing for bone marrow transplant

Memorial Sloan Kettering Cancer Center is starting a new clinical trial of A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant.

The purpose of this study is to see if conditioning regimens that include personalized rabbit ATG (P-rATG) help the immune system recover sooner and decrease the chances of transplant-related side effects. Participants in this study will be children and adults who have acute leukemia or myelodysplastic syndrome (MDS), and they will receive a standard conditioning regimen to prepare the body for an allogeneic hematopoietic cell transplant (allo-HCT). The conditioning regimen will include r-ATG, one of two combinations of chemotherapy, and possibly total body irradiation (TBI).

The clinical trial started in April 30, 2021 and will continue throughout April 2024.

The contacts and locations are the Memorial Sloan Kettering Cancer Center, New York, New York, United States. For study locations, inclusion and exclusion criteris please see the link:

Clinical Research News

Upcoming Clinical Trials